Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo To Revamp Prasugrel's U.S. Marketing After Sluggish Sales

This article was originally published in PharmAsia News

Executive Summary

TOKYO - An 11.1 percent upward operating income revision to ¥100 billion notwithstanding, Daiichi Sankyo is streamlining its U.S. marketing strategy for platelet inhibitor Effient (prasugrel) as the drug's July-September U.S. and European sales remained a humble ¥1.8 billion, a company spokesman said Nov. 2

You may also be interested in...



Eisai's Regional Shift, Or Just Restructuring? Daiichi Sankyo's U.S. Ranbaxy Dip: Japanese Earnings Roundup (Part 2 of 2)

[Editor's note: This is part two of a two-part feature on Japanese pharma earnings; part one covered Dainippon Sumitomo Pharma Co. Ltd. and its failed pan-Asia trials and Mitsubishi Tanabe Pharma Corp.'s efforts to rebound from Japan's March 11 earthquake. This second part covers Eisai Co. Ltd. and Daiichi Sankyo Co. Ltd.]

Eisai's Regional Shift, Or Just Restructuring? Daiichi Sankyo's U.S. Ranbaxy Dip: Japanese Earnings Roundup (Part 2 of 2)

[Editor's note: This is part two of a two-part feature on Japanese pharma earnings; part one covered Dainippon Sumitomo Pharma Co. Ltd. and its failed pan-Asia trials and Mitsubishi Tanabe Pharma Corp.'s efforts to rebound from Japan's March 11 earthquake. This second part covers Eisai Co. Ltd. and Daiichi Sankyo Co. Ltd.]

Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.

TOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel